Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BIMEKIZUMAB Cause Product availability issue? 54 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 54 reports of Product availability issue have been filed in association with BIMEKIZUMAB (Bimzelx). This represents 2.2% of all adverse event reports for BIMEKIZUMAB.

54
Reports of Product availability issue with BIMEKIZUMAB
2.2%
of all BIMEKIZUMAB reports
0
Deaths
8
Hospitalizations

How Dangerous Is Product availability issue From BIMEKIZUMAB?

Of the 54 reports, 8 (14.8%) required hospitalization.

Is Product availability issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BIMEKIZUMAB. However, 54 reports have been filed with the FAERS database.

What Other Side Effects Does BIMEKIZUMAB Cause?

Psoriatic arthropathy (615) Psoriasis (400) Drug ineffective (293) Inappropriate schedule of product administration (238) Injection site pain (225) Product dose omission issue (163) Off label use (160) Oral candidiasis (146) Fatigue (138) Therapy interrupted (138)

What Other Drugs Cause Product availability issue?

RUXOLITINIB (2,142) LISDEXAMFETAMINE DIMESYLATE (1,530) CERTOLIZUMAB PEGOL (1,381) VEDOLIZUMAB (636) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (610) METHYLPHENIDATE (444) SECUKINUMAB (399) BIMEKIZUMAB-BKZX (364) LACOSAMIDE (359) BRIVARACETAM (324)

Which BIMEKIZUMAB Alternatives Have Lower Product availability issue Risk?

BIMEKIZUMAB vs BIMEKIZUMAB-BKZX BIMEKIZUMAB vs BINIMETINIB BIMEKIZUMAB vs BIOFLAVONOIDS BIMEKIZUMAB vs BIOTIN BIMEKIZUMAB vs BIPERIDEN

Related Pages

BIMEKIZUMAB Full Profile All Product availability issue Reports All Drugs Causing Product availability issue BIMEKIZUMAB Demographics